Allay Therapeutics Appoints Nicole Vitullo to Board of Directors

SAN JOSE, Calif.--(BUSINESS WIRE)--Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the appointment of Nicole Vitullo, venture partner at Arboretum Ventures, to its board of directors.

“We’re thrilled to have Nicole join the Allay board and appreciate the continued support of Arboretum Ventures as we work to change the pain management paradigm and dramatically improve the post-surgical recovery experience for patients,” said Adam Gridley, Chief Executive Officer of Allay Therapeutics. “Nicole’s counsel, drawing from her long experience working with advanced-stage and commercial-stage biopharma companies, will be invaluable as we continue clinical development of our lead candidate ATX101 and advance additional Allay products into clinical studies worldwide.”

Nicole is a longtime biotech investor and company advisor with extensive experience in both public and private investing, as a Partner with Domain Associates, a venture capital firm focused in the life sciences sector. She joined Arboretum as a venture partner in 2023. Nicole currently serves on the board of Esperion Therapeutics and Hinge Bio Inc. Her past board memberships include numerous companies that have entered transactions, including Achillion Pharmaceuticals (Alexion), Calixa Therapeutics (Cubist Pharmaceuticals), Celator Pharmaceuticals (Jazz Pharmaceuticals), Cerexa (Forest Laboratories), Durata Therapeutics (Actavis), Marinus Pharmaceuticals, Onyx Pharmaceuticals, and VentiRx Pharmaceuticals (Celgene). Nicole holds a bachelor’s degree in mathematics and MBA from the University of Rochester.

“I’m excited to be part of Allay’s mission to develop medicines that help patients through extended painful recoveries and reduce their reliance on opioids following surgery. There is a huge unmet need for therapies that not only provide pain relief but also offer peace of mind for patients and their caregivers,” said Ms. Vitullo. “I look forward to working with Adam and the team as they work to bring these innovations to patients, providers and payors.”

About Allay Therapeutics

Allay Therapeutics is pioneering a new category of ultra-sustained pain therapeutics to transform post-surgical pain management and recuperation for patients and physicians. Allay’s proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable therapeutics to deliver pain relief within a targeted site over weeks—an order of magnitude greater than the longest-lasting pain treatments currently available. The company’s lead investigational product candidate, ATX101, is currently being evaluated in a Phase 2 clinical study in total knee arthroplasties (TKA, also called total knee replacements). Allay unites a dynamic, global team of entrepreneurs, scientists, clinicians and innovators in the San Francisco Bay Area and Singapore. Learn more at allaytx.com.